Ask AI
ProCE Banner Activity

Una iniziativa internazionale per migliorare la cura della LLC recidivata/refrattaria

PDF

Nella valutazione che segue 3 specialisti esperti di LLC riconosciuti internazionalmente, rispondono alle domande cliniche più urgenti e frequenti che emergono nell'era moderna delle terapie target. I loro approfondimenti sul piano pratico offrono indicazioni su sequenza terapeutica, valutazione della resistenza, uso dei biomarcatori e sfide gestionali reali nel trattamento della LLC recidivata/refrattaria.

Released: February 12, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Lymphoma Coalition.

ProCE Banner

Supporters

Supported by educational grants from Lilly and Merck Sharp & Dohme LLC.

Lilly

Merck Sharp & Dohme, LLC

Partners

Lymphoma Coalition

ProCE Banner

Target Audience

This activity has been designed to meet the educational needs of global hematologists, oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals caring for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan individualized treatment sequences to optimize clinical outcomes for patients with relapsed/refractory CLL/SLL, considering available evidence, local expert recommendations, regional guidelines, and disease/patient factors

  • Appraise emerging clinical evidence for novel BTK-targeted therapies and the clinical implications for management of relapsed/refractory CLL/SLL

  • Assess resistance mutations in patients with relapsed/refractory CLL/SLL who progressed on or following covalent BTK inhibitor therapy

  • Implement multidisciplinary team processes to mitigate the risk of treatment- and disease-related complications in patients with relapsed/refractory CLL/SLL

  • Apply shared decision-making strategies to support patient quality of life and engagement in care for relapsed/refractory CLL/SLL

Disclosure

Primary Author

Stéphane Lepretre, MD, has no relevant financial relationships to disclose.

Stephen Stilgenbauer, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Galapagos, Gilead, GSK, Hoffmann-La Roche, Johnson & Johnson; researcher: AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Galapagos, Gilead, GSK, Hoffmann-La Roche, Johnson & Johnson.

Alessandra Tedeschi, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Johnson & Johnson, Lilly.